Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 9 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (1)
P 1 (4)
P 2 (1)
P 3 (2)

Trial Status

Completed7
Recruiting1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06834997Phase 2Withdrawn

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06795243Not ApplicableRecruiting

Efficacy of Physical Therapy Treatment in Endometriosis and Its Relationship to Adherence Rates.

NCT04471337Phase 1CompletedPrimary

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04265781Phase 1CompletedPrimary

Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

NCT04487431Phase 1CompletedPrimary

A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)

NCT04454424Phase 1CompletedPrimary

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT03204318Phase 3CompletedPrimary

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204331Phase 3CompletedPrimary

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03779256CompletedPrimary

Bowel ENDOmetriosis; Evaluation of Diagnostics and Quality of Life

Showing all 9 trials

Research Network

Activity Timeline